Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acute Respiratory Distress Syndrome-Pipeline Review, H1 2015

Acute Respiratory Distress Syndrome-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Acute Respiratory Distress Syndrome-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Respiratory Distress Syndrome-Pipeline Review, H1 2015', provides an overview of the Acute Respiratory Distress Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acute Respiratory Distress Syndrome Overview 9

Therapeutics Development 10

Pipeline Products for Acute Respiratory Distress Syndrome-Overview 10

Pipeline Products for Acute Respiratory Distress Syndrome-Comparative Analysis 11

Acute Respiratory Distress Syndrome-Therapeutics under Development by Companies 12

Acute Respiratory Distress Syndrome-Therapeutics under Investigation by Universities/Institutes 13

Acute Respiratory Distress Syndrome-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Acute Respiratory Distress Syndrome-Products under Development by Companies 16

Acute Respiratory Distress Syndrome-Products under Investigation by Universities/Institutes 18

Acute Respiratory Distress Syndrome-Companies Involved in Therapeutics Development 19

Altor BioScience Corporation 19

BioMarck Pharmaceuticals, Ltd. 20

Faron Pharmaceuticals Oy 21

FirstString Research, Inc. 22

GlaxoSmithKline plc 23

Histocell S.L. 24

Mallinckrodt plc 25

Myelo Therapeutics GmbH 26

Navigen Pharmaceuticals, Inc. 27

Phylogica Limited 28

Serendex Pharmaceuticals A/S 29

Therabron Therapeutics, Inc. 30

Therametrics holding AG 31

Acute Respiratory Distress Syndrome-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

ALT-836-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

BIO-10901-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

CG-367-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

corticotropin-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

DasKloster-0141-01-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

DasKloster-100004-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

dilmapimod-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

GSK-2586881-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

GSK-2862277-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

interferon beta-1a-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

molgramostim-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Monoclonal Antibody to Inhibit E-selectin for Acute Respiratory Distress Syndrome-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Myelo-001-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

perfluorocarbon-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

PYC-35-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

PYC-36-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

PYC-38-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

PYC-98-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

S-1229-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Slit2N-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Small Molecules for Inflammatory Diseases and Sepsis-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Stem Cell Therapy for Inflammatory Lung Diseases-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Stromal Cell Therapy for Acute Respiratory Distress Syndrome-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Acute Respiratory Distress Syndrome-Recent Pipeline Updates 73

Acute Respiratory Distress Syndrome-Dormant Projects 77

Acute Respiratory Distress Syndrome-Discontinued Products 79

Acute Respiratory Distress Syndrome-Product Development Milestones 80

Featured News & Press Releases 80

Dec 20, 2013: Faron receives scientific advise from the EMA on the FP-1201-lyo clinical development 80

Oct 22, 2013: Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome 80

Nov 29, 2012: Faron Pharma Receives 6m Grant From European Commission For Traumakine Program 81

May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 AmericanThoracic Society Meeting 81

Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 82

May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 82

Apr 12, 2011: Faron Completes Recruitment For Phase I/II Clinical Trial Of FP-1201 83

Jan 17, 2011: Rentschler And Faron Pharma Sign Manufacturing And Supply Agreement For Traumakine 83

Sep 16, 2010: Faron's Lead Product FP-1201 Enters Next Phase Of Study 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2015 10

Number of Products under Development for Acute Respiratory Distress Syndrome-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Development by Companies, H1 2015 (Contd..1) 17

Products under Investigation by Universities/Institutes, H1 2015 18

Acute Respiratory Distress Syndrome-Pipeline by Altor BioScience Corporation, H1 2015 19

Acute Respiratory Distress Syndrome-Pipeline by BioMarck Pharmaceuticals, Ltd., H1 2015 20

Acute Respiratory Distress Syndrome-Pipeline by Faron Pharmaceuticals Oy, H1 2015 21

Acute Respiratory Distress Syndrome-Pipeline by FirstString Research, Inc., H1 2015 22

Acute Respiratory Distress Syndrome-Pipeline by GlaxoSmithKline plc, H1 2015 23

Acute Respiratory Distress Syndrome-Pipeline by Histocell S.L., H1 2015 24

Acute Respiratory Distress Syndrome-Pipeline by Mallinckrodt plc, H1 2015 25

Acute Respiratory Distress Syndrome-Pipeline by Myelo Therapeutics GmbH, H1 2015 26

Acute Respiratory Distress Syndrome-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 27

Acute Respiratory Distress Syndrome-Pipeline by Phylogica Limited, H1 2015 28

Acute Respiratory Distress Syndrome-Pipeline by Serendex Pharmaceuticals A/S, H1 2015 29

Acute Respiratory Distress Syndrome-Pipeline by Therabron Therapeutics, Inc., H1 2015 30

Acute Respiratory Distress Syndrome-Pipeline by Therametrics holding AG, H1 2015 31

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Stage and Target, H1 2015 34

Number of Products by Stage and Mechanism of Action, H1 2015 36

Number of Products by Stage and Route of Administration, H1 2015 38

Number of Products by Stage and Molecule Type, H1 2015 40

Acute Respiratory Distress Syndrome Therapeutics-Recent Pipeline Updates, H1 2015 73

Acute Respiratory Distress Syndrome-Dormant Projects, H1 2015 77

Acute Respiratory Distress Syndrome-Dormant Projects (Contd..1), H1 2015 78

Acute Respiratory Distress Syndrome-Discontinued Products, H1 2015 79

List of Figures

Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2015 10

Number of Products under Development for Acute Respiratory Distress Syndrome-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Top 10 Targets, H1 2015 33

Number of Products by Stage and Top 10 Targets, H1 2015 34

Number of Products by Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 36

Number of Products by Top 10 Routes of Administration, H1 2015 37

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 38

Number of Products by Top 10 Molecule Types, H1 2015 39

Number of Products by Stage and Top 10 Molecule Types, H1 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Altor BioScience Corporation

BioMarck Pharmaceuticals, Ltd.

Faron Pharmaceuticals Oy

FirstString Research, Inc.

GlaxoSmithKline plc

Histocell S.L.

Mallinckrodt plc

Myelo Therapeutics GmbH

Navigen Pharmaceuticals, Inc.

Phylogica Limited

Serendex Pharmaceuticals A/S

Therabron Therapeutics, Inc.

Therametrics holding AG

Acute Respiratory Distress Syndrome Therapeutic Products under Development, Key Players in Acute Respiratory Distress Syndrome Therapeutics, Acute Respiratory Distress Syndrome Pipeline Overview, Acute Respiratory Distress Syndrome Pipeline, Acute Respiratory Distress Syndrome Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com